FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.
| Drug | Indication | Phase | Status |
|---|---|---|---|
| Apalutamide | Castration-Resistant Prostate Cancer (CRPC) | PHASE2 | RECRUITING |
| Oral MRT-2359 | Castration-Resistant Prostate Cancer (CRPC) | PHASE2 | RECRUITING |
| MRT-6160 | Healthy Volunteers | PHASE1 | COMPLETED |
| MRT-8102 | Healthy Volunteers | PHASE1 | ACTIVE_NOT_RECRUITING |
GLUE holds $90.1M in cash and burns about $40.7M/quarter from operations, giving an estimated runway of 6.6 months. A recent offering filing was detected — dilution watch.
Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for GLUE free →
| Date | Insider | Type | Value |
|---|---|---|---|
| 2026-07-17 | Warmuth Markus |
Sale | $13.6M |
| 2026-07-16 | Champoux Jennifer |
Purchase | $265,554 |
| 2026-07-16 | Champoux Jennifer |
Sale | $1.5M |
| 2026-07-16 | Champoux Jennifer |
Sale | $0 |
| 2026-07-07 | Townson Sharon |
Purchase | $453,408 |
A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for GLUE and 2 more tickers of your choice.
Create Free Account →